Takeda Liable In IBS Drug Pay-For-Delay Trial
A federal jury in Boston on Monday found Takeda Pharmaceuticals conspired with a generic-drug maker to delay the launch of a generic version of Takeda's anti-constipation drug, awarding purchasers $885 million, a...To view the full article, register now.
Already a subscriber? Click here to view full article